The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Noninvasive Prenatal Diagnostics Market Research Report 2024
Synopsis
Noninvasive Prenatal Diagnostics detect a variety of chromosomal disorders such as Down's syndrome, Edwards syndrome, Turner syndrome and Pato syndrome.
The global Noninvasive Prenatal Diagnostics market was valued at US$ 8436.5 million in 2023 and is anticipated to reach US$ 19210 million by 2030, witnessing a CAGR of 12.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Noninvasive Prenatal Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Prenatal Diagnostics.
Report Scope
The Noninvasive Prenatal Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Noninvasive Prenatal Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Noninvasive Prenatal Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Natera
Illumina
BGI Diagnosis
Ariosa Diagnostics
Quest Diagnostics
Premaitha Health
NIPD Genetics
Labcorp
Ravgen
LifeCodexx
TrovaGene
Berry Genomics
Segment by Type
Services
Instrument
Segment by Application
Hospital
Personal
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Noninvasive Prenatal Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Noninvasive Prenatal Diagnostics detect a variety of chromosomal disorders such as Down's syndrome, Edwards syndrome, Turner syndrome and Pato syndrome.
The global Noninvasive Prenatal Diagnostics market was valued at US$ 8436.5 million in 2023 and is anticipated to reach US$ 19210 million by 2030, witnessing a CAGR of 12.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Noninvasive Prenatal Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Prenatal Diagnostics.
Report Scope
The Noninvasive Prenatal Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Noninvasive Prenatal Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Noninvasive Prenatal Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Natera
Illumina
BGI Diagnosis
Ariosa Diagnostics
Quest Diagnostics
Premaitha Health
NIPD Genetics
Labcorp
Ravgen
LifeCodexx
TrovaGene
Berry Genomics
Segment by Type
Services
Instrument
Segment by Application
Hospital
Personal
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Noninvasive Prenatal Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Noninvasive Prenatal Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Services
1.2.3 Instrument
1.3 Market by Application
1.3.1 Global Noninvasive Prenatal Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Personal
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Noninvasive Prenatal Diagnostics Market Perspective (2019-2030)
2.2 Noninvasive Prenatal Diagnostics Growth Trends by Region
2.2.1 Global Noninvasive Prenatal Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Noninvasive Prenatal Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Noninvasive Prenatal Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Noninvasive Prenatal Diagnostics Market Dynamics
2.3.1 Noninvasive Prenatal Diagnostics Industry Trends
2.3.2 Noninvasive Prenatal Diagnostics Market Drivers
2.3.3 Noninvasive Prenatal Diagnostics Market Challenges
2.3.4 Noninvasive Prenatal Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Noninvasive Prenatal Diagnostics Players by Revenue
3.1.1 Global Top Noninvasive Prenatal Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Noninvasive Prenatal Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Noninvasive Prenatal Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Noninvasive Prenatal Diagnostics Revenue
3.4 Global Noninvasive Prenatal Diagnostics Market Concentration Ratio
3.4.1 Global Noninvasive Prenatal Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Noninvasive Prenatal Diagnostics Revenue in 2023
3.5 Noninvasive Prenatal Diagnostics Key Players Head office and Area Served
3.6 Key Players Noninvasive Prenatal Diagnostics Product Solution and Service
3.7 Date of Enter into Noninvasive Prenatal Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Noninvasive Prenatal Diagnostics Breakdown Data by Type
4.1 Global Noninvasive Prenatal Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Noninvasive Prenatal Diagnostics Forecasted Market Size by Type (2025-2030)
5 Noninvasive Prenatal Diagnostics Breakdown Data by Application
5.1 Global Noninvasive Prenatal Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Noninvasive Prenatal Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Noninvasive Prenatal Diagnostics Market Size (2019-2030)
6.2 North America Noninvasive Prenatal Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Noninvasive Prenatal Diagnostics Market Size by Country (2019-2024)
6.4 North America Noninvasive Prenatal Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Noninvasive Prenatal Diagnostics Market Size (2019-2030)
7.2 Europe Noninvasive Prenatal Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Noninvasive Prenatal Diagnostics Market Size by Country (2019-2024)
7.4 Europe Noninvasive Prenatal Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Noninvasive Prenatal Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Noninvasive Prenatal Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Noninvasive Prenatal Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Noninvasive Prenatal Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Noninvasive Prenatal Diagnostics Market Size (2019-2030)
9.2 Latin America Noninvasive Prenatal Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Noninvasive Prenatal Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Noninvasive Prenatal Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Noninvasive Prenatal Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Noninvasive Prenatal Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Noninvasive Prenatal Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Noninvasive Prenatal Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Natera
11.1.1 Natera Company Detail
11.1.2 Natera Business Overview
11.1.3 Natera Noninvasive Prenatal Diagnostics Introduction
11.1.4 Natera Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.1.5 Natera Recent Development
11.2 Illumina
11.2.1 Illumina Company Detail
11.2.2 Illumina Business Overview
11.2.3 Illumina Noninvasive Prenatal Diagnostics Introduction
11.2.4 Illumina Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.2.5 Illumina Recent Development
11.3 BGI Diagnosis
11.3.1 BGI Diagnosis Company Detail
11.3.2 BGI Diagnosis Business Overview
11.3.3 BGI Diagnosis Noninvasive Prenatal Diagnostics Introduction
11.3.4 BGI Diagnosis Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.3.5 BGI Diagnosis Recent Development
11.4 Ariosa Diagnostics
11.4.1 Ariosa Diagnostics Company Detail
11.4.2 Ariosa Diagnostics Business Overview
11.4.3 Ariosa Diagnostics Noninvasive Prenatal Diagnostics Introduction
11.4.4 Ariosa Diagnostics Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.4.5 Ariosa Diagnostics Recent Development
11.5 Quest Diagnostics
11.5.1 Quest Diagnostics Company Detail
11.5.2 Quest Diagnostics Business Overview
11.5.3 Quest Diagnostics Noninvasive Prenatal Diagnostics Introduction
11.5.4 Quest Diagnostics Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.5.5 Quest Diagnostics Recent Development
11.6 Premaitha Health
11.6.1 Premaitha Health Company Detail
11.6.2 Premaitha Health Business Overview
11.6.3 Premaitha Health Noninvasive Prenatal Diagnostics Introduction
11.6.4 Premaitha Health Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.6.5 Premaitha Health Recent Development
11.7 NIPD Genetics
11.7.1 NIPD Genetics Company Detail
11.7.2 NIPD Genetics Business Overview
11.7.3 NIPD Genetics Noninvasive Prenatal Diagnostics Introduction
11.7.4 NIPD Genetics Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.7.5 NIPD Genetics Recent Development
11.8 Labcorp
11.8.1 Labcorp Company Detail
11.8.2 Labcorp Business Overview
11.8.3 Labcorp Noninvasive Prenatal Diagnostics Introduction
11.8.4 Labcorp Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.8.5 Labcorp Recent Development
11.9 Ravgen
11.9.1 Ravgen Company Detail
11.9.2 Ravgen Business Overview
11.9.3 Ravgen Noninvasive Prenatal Diagnostics Introduction
11.9.4 Ravgen Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.9.5 Ravgen Recent Development
11.10 LifeCodexx
11.10.1 LifeCodexx Company Detail
11.10.2 LifeCodexx Business Overview
11.10.3 LifeCodexx Noninvasive Prenatal Diagnostics Introduction
11.10.4 LifeCodexx Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.10.5 LifeCodexx Recent Development
11.11 TrovaGene
11.11.1 TrovaGene Company Detail
11.11.2 TrovaGene Business Overview
11.11.3 TrovaGene Noninvasive Prenatal Diagnostics Introduction
11.11.4 TrovaGene Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.11.5 TrovaGene Recent Development
11.12 Berry Genomics
11.12.1 Berry Genomics Company Detail
11.12.2 Berry Genomics Business Overview
11.12.3 Berry Genomics Noninvasive Prenatal Diagnostics Introduction
11.12.4 Berry Genomics Revenue in Noninvasive Prenatal Diagnostics Business (2019-2024)
11.12.5 Berry Genomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
